Skip to main content

Advertisement

Table 3 Common variants in MBL2 and odds ratio for being HCV RNA negative among injection drug users

From: MBL2and Hepatitis C Virus Infection among Injection Drug Users

   European Americans African Americans
Locus Genotype HCV RNA Negative % HCV RNA Positive % OR (95% CI) HCV RNA Negative % HCV RNA Positive % OR (95% CI)
T-1964C            
  TT 83 77.6 256 76.0 1.00 82 93.2 288 94.1 1.00
  TC 23 21.5 73 21.7 0.94 (0.55–1.60) 6 6.8 17 5.6 1.27 (0.48–3.36)
  CC 1 0.9 8 2.4 0.44 (0.05–3.51) 0 0.0 1 0.3 NA
  TC + CC 24 22.4 81 24.0 0.91 (0.54–1.53) 6 6.8 18 5.9 1.20 (0.46–3.14)
G-618C (H/L)            
  CC 44 41.9 124 36.4 1.00 69 80.2 233 76.9 1.00
  CG 47 44.8 164 48.1 0.80 (0.50–1.29) 15 17.4 67 22.1 0.76 (0.41–1.42)
  GG 14 13.3 53 15.5 0.72 (0.36–1.43) 2 2.2 3 1.0 2.63 (0.42–16.43)
  CG + GG 61 58.1 217 63.6 0.80 (0.51–1.26) 17 19.8 70 23.1 0.83 (0.46–1.50)
G-289C (Y/X)            
  GG 59 55.1 218 66.3 1.00 63 71.6 218 70.6 1.00
  GC 42 39.3 103 31.3 1.56 (0.98–2.49) 23 26.1 87 28.2 0.92 (0.53–1.58)
  CC 6 5.6 8 2.4 2.72 (0.90–8.23) 2 2.3 4 1.3 2.01 (0.35–11.42)
  GC + CC 48 44.9 111 33.7 1.65 (1.05–2.58) 25 28.4 91 29.4 0.97 (0.57–1.63)
T-65C (P/Q)            
  CC 64 59.8 197 57.4 1.00 21 23.9 64 20.8 1.00
  CT 38 35.5 127 37.0 0.93 (0.59–1.48) 43 48.9 160 51.9 0.81 (0.44–1.48)
  TT 5 5.0 19 5.5 0.75 (0.27–2.09) 24 27.3 84 27.3 0.85 (0.43–1.67)
  CT + TT 43 4.7 146 42.6 0.90 (0.58–1.40) 67 76.1 244 79.2 0.83 (0.47–1.47)
Ex1 C-34T (D)            
  CC 95 87.2 300 87.5 1.00 87 97.8 303 98.1 1.00
  TC 13 11.9 42 12.2 1.06 (0.54–2.10) 2 2.3 6 1.9 1.11 (0.22–5.62)
  TT 1 0.9 1 0.3 2.71 (0.16–45.25) 0 0.0 0 0.0 NA
  TC + TT 14 12.8 43 12.5 1.00 (0.52–1.91) 2 2.3 6 1.9 1.11 (0.22–5.62)
Ex1 G-27A (B)            
  GG 85 78.0 256 75.5 1.00 83 93.3 285 93.4 1.00
  GA 23 21.1 75 22.1 0.90 (0.53–1.53) 6 6.7 19 6.2 1.10 (0.42–2.86)
  AA 1 0.9 8 2.4 0.42 (0.05–3.46) 0 0.0 1 0.3 NA
  GA + AA 24 22.0 83 24.5 0.87 (0.52–1.46) 6 6.7 20 6.6 1.04 (0.40–2.70)
Ex1 G-18A (C)            
  GG 95 92.2 312 96.0 1.00 49 56.3 168 55.6 1.00
  GA 8 7.8 13 4.0 2.26 (0.89–5.73) 29 33.3 116 38.4 0.86 (0.51–1.45)
  AA 0 0.0 0 0.0 NA 9 10.3 18 6.0 1.68 (0.71–3.99)
  GA + AA 8 7.8 13 4.0 2.26 (0.89–5.73) 38 43.7 134 44.4 0.97 (0.60–1.57)
IVS2 G-630A            
  GG 22 20.8 59 17.9 1.00 49 57.6 168 54.4 1.00
  GA 55 51.9 161 48.8 0.89 (0.50–1.59) 31 36.5 127 41.1 0.84 (0.51–1.39)
  AA 29 27.4 110 33.3 0.68 (0.36–1.30) 5 5.9 14 4.5 1.22 (0.41–3.60)
  GA + AA 84 79.3 271 82.1 0.82 (0.47–1.43) 36 42.4 141 45.6 0.87 (0.54–1.42)
IVS2 T-250C            
  TT 42 40.4 119 35.6 1.00 72 80.9 236 76.9 1.00
  TC 48 46.2 161 48.2 0.84 (0.52–1.36) 15 16.9 68 22.2 0.73 (0.39–1.36)
  CC 14 13.5 54 16.2 0.72 (0.36–1.43) 2 2.3 3 1.0 2.52 (0.40–15.75)
  TC + CC 62 59.6 215 64.4 0.83 (0.53–1.31) 17 19.1 71 23.1 0.79 (0.44–1.43)
IVS3 G-28C            
  GG 72 66.7 239 70.7 1.00 36 41.9 135 43.8 1.00
  GC 34 31.5 93 27.5 1.28 (0.79–2.07) 39 45.3 144 46.8 1.02 (0.61–1.70)
  CC 2 1.9 6 1.8 0.98 (0.19–5.00) 11 12.8 29 9.4 1.42 (0.65–3.14)
  GC +CC 36 33.3 99 29.3 1.25 (0.78–1.99) 50 58.1 173 56.2 1.08 (0.66–1.76)
Ex4 C+5G            
  GG 70 66.7 244 71.6 1.00 41 46.1 143 46.6 1.00
  GC 33 31.4 92 27.0 1.31 (0.81–2.14) 39 43.8 138 45.0 0.98 (0.60–1.62)
  CC 2 1.9 5 1.5 1.17 (0.22–6.27) 9 10.1 26 8.5 1.22 (0.53–2.82)
  GC + CC 35 33.3 97 28.4 1.32 (0.82–2.11) 48 53.9 164 53.4 1.02 (0.63–1.64)
Ex4 T-1483C            
  TT 65 60.2 193 58.5 1.00 25 28.7 88 29.6 1.00
  TC 36 33.3 117 35.5 0.91 (0.57–1.47) 32 36.8 155 52.2 0.72 (0.40–1.30)
  CC 7 6.5 20 6.1 1.13 (0.45–2.83) 30 34.5 54 18.2 2.02 (1.07–3.81)
  TC + CC 43 39.8 137 41.5 0.94 (0.60–1.47) 62 71.3 209 70.4 1.05 (0.62–1.79)
Ex4 G-1067A            
  GG 18 17.5 46 13.8 1.00 62 72.9 199 65.9 1.00
  GA 48 46.6 156 46.8 0.72 (0.38–1.37) 19 22.4 92 30.5 0.67 (0.38–1.20)
  AA 37 35.9 131 39.3 0.65 (0.33–1.26) 4 4.7 11 3.6 1.31 (0.40–4.32)
  GA +AA 85 82.5 287 86.2 0.70 (0.38–1.28) 23 27.1 103 34.1 0.73 (0.43–1.25)
Ex4 G-901A            
  AA 61 58.1 187 57.0 1.00 26 29.2 90 29.8 1.00
  GA 37 35.2 118 36.0 0.97 (0.60–1.55) 35 39.3 160 53.0 0.75 (0.42–1.33)
  GG 7 6.7 23 7.0 1.02 (0.41–2.52) 28 31.5 52 17.2 1.87 (0.99–3.53)
  GA + GG 44 41.9 141 43.0 0.69 (0.61–1.51) 63 70.8 212 70.2 1.03 (0.61–1.73)
Ex4 G-710A            
  AA 65 60.7 196 58.3 1.00 18 20.2 65 21.3 1.00
  GA 34 31.8 120 35.7 0.86 (0.54–1.39) 34 38.2 150 49.2 0.82 (0.43–1.56)
  GG 8 7.5 20 6.0 1.31 (0.55–3.17) 37 41.6 90 29.5 1.50 (0.78–2.88)
  GA + GG 42 39.3 140 41.7 0.92 (0.59–1.44) 71 79.8 240 78.7 1.07 (0.60–1.93)
  1. NOTE: The most frequent homozygotes among controls served as the referent. Genotypic odds ratios were adjusted for sex, duration of injection drug use, and HIV-serostatus; OR (odds ratio); 95% CI (confidence interval); and NA, not applicable.